...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gynaecological oncology >Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia
【24h】

Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia

机译：人乳头瘤病毒疫苗接种对高级宫颈上皮内瘤形成术后的患者的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: To test whether the human papillomavirus (HPV) vaccination in patients undergoing loop diathermy conization (LEEP) for high-grade intraepithelial neoplasia (CIN 2-3) is effective in preventing recurrence of CIN 2-3 in our area. Materials and Methods: A retrospective review was conducted on 242 patients undergoing LEEP for CIN 2-3 and 42.6% received the HPV vaccine (bivalent or tetravalent) immediately before or after conization. Follow up was conducted at 3, 6, 12, 18, and 24 months to detect CIN 2-3 recurrence. Results: Regardless of the HPV type, 27 (11.1%) patients developed CIN 2-3 recurrence during post-LEEP follow up. Of the 70 vaccinated with bivalent vaccine, two (2.8%) showed recurrence, of the 33 vaccinated with tetravalent vaccine, three (9%), and of the 139 unvaccinated 61 (43.9%) developed recurrence. Of the patients infected with HPV genotypes 16/18, in the non-vaccinated group, 15 (21.7%) patients had recurrence, whereas in the vaccinated group, three (5.9%) were diagnosed with recurrence (p < 0/05). The multivariate logistic regression analysis showed that the vaccination acted as a protective factor for CIN 2-3 recurrence (OR: 0.360 (95% CI: 0.125-1.000; p < 0.05). However, neither the type of vaccine nor the time of vaccination showed a significant association with the onset of recurrence. Conclusions: The HPV vaccine appears to be a recommendable preventative strategy in reducing the risk of recurrent disease for patients treated for CIN 2-3.
机译：目的：测试在伴随着循环透析（LEEP）的患者中的人乳头瘤病毒（HPV）疫苗接种是否有效地在我们该地区预防CIN 2-3的复发。材料和方法：在接受CIEP的242名患者中进行了回顾性审查，42.6％在截然之前或之​​后接受了HPV疫苗（二价或四价）。随访于3,6,12,18和24个月进行，以检测CIN 2-3复发。结果：无论HPV型，27例（11.1％）患者在后续行动后开发了CIN 2-3复发。在与二价疫苗接种疫苗的70中，两（2.8％）显示出复发，33与四价疫苗接种，三（9％）和139个未接种的61（43.9％）发育复发。在感染HPV基因型16/18的患者中，在非疫苗基团中，15名（21.7％）患者的复发性，而在疫苗基团中，诊断出三次（5.9％）复发（P <0/05）。多变量逻辑回归分析表明，疫苗接种作为CIN 2-3复发的保护因子（或：0.360（95％CI：0.125-1.000; P <0.05）。但是，疫苗的类型也不是疫苗接种的时间表现出与复发发生的重大关联。结论：HPV疫苗似乎是一种推荐的预防措施，以降低用于治疗CIN 2-3的患者的复发性疾病风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号